Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Nasdaq Biotechnology Ishares ETF (NQ: IBB)
102.35 USD  -0.11 (-0.11%)
Official Closing Price  /  Updated: 5:06 PM EDT, Oct 16, 2019  /  Add to My Watchlist      
View: Quote News
Fund Overview
Nasdaq Biotechnology Ishares ETF
Sector
Exchange Traded NQ
Net Assets 8.90B
Inception Date
Related Funds
Quote
Price 102.35
Volume 2,238,573
Last Trade Oct 16, 5:06pm
Change (%)
-0.11 (-0.11%)
Prev. Close 102.46
YTD %
+4.97%
Dividend Yield 0.31%
Performance
YTD
+4.85 (4.97%)
1 Month
-2.79 (-2.65%)
3 Month
-3.12 (-2.96%)
6 Month
-7.04 (-6.44%)
1 Year
-7.74 (-7.03%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... Read More
from Benzinga
Market Charges Higher Led By Healthcare Sector
The healthcare sector, led by ETFs like the SPDR Health Care ETF (XLV), is helping to drive stocks higher on Tuesday, along with technology. XLV is up over 1.67%, as reported earnings from several... Read More
from ETF Trends
Top News
More News
The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that ... Read More
from Benzinga
Financial Advisor On ETF Strategies To Deploy
Patrick Healey of Caliber Financial Partners shares how he's deploying ETFs in client portfolios and why he's so focused on the biotech sector. Read More
from Investor's Business Daily
Monday's ETF Movers: IBB, XOP
In trading on Monday, the iShares Nasdaq Biotechnology ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Adverum... Read More
from ETF Channel
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed ... Read More
from Benzinga
Stock Market Theme - Collect $200 Or Go Directly To Jail
The market feels like an X rated version of Monopoly, only instead of buying and trading properties, we are buying and trading headlines. Buy or trade it correctly and you can easily collect $200. Do... Read More
from Blogs - TalkMarkets
VC Money Is Flowing Into Biotechs
Venture capitalists are pouring cash into U.S. biotechs at a rate set to replicate 2018’s record deal count, according to ... Read More
from Benzinga
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
The following is aroundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech ... Read More
from Benzinga
These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls
Sen. Elizabeth Warren’s health-care reform crusade is rattling biotech investors — but that’s not the industry’s only problem, writes Michael Brush. Read More
from MarketWatch
Salmon on Ice; Is it Time to Buy China & Sell the US?
The bigger theory on this hedge is that ultimately, China outperforms the U.S. regardless of the trade outcome. Read More
from Blogs - TalkMarkets
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting ... Read More
from Benzinga
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
The following is aroundup of top developments in the biotech space over the last 24 hours. None of the NYSE or ... Read More
from Benzinga
Analysts See 40% Upside For The Holdings of IBB
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... Read More
from ETF Channel
The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... Read More
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.